QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Walter in HK who wrote (729)	11/16/1999 8:56:00 AM
From: Julian	Read Replies (1) of 1321

NOT DEAF!!! NP says QLT's Visudyne to be reviewed tomorrow QLT PhotoTherapeutics Inc QLT Shares issued 28,385,597 Nov 15 close $57.70 Tue 16 Nov 99 In the News The National Post reports in its Tuesday edition that analyst Lennox Gibbs at CIBC World Markets Inc. in Toronto has reiterated his "strong buy" rating on QLT shares. Mr. Gibbs has a 12-month price target of $79 on the stock. Tomorrow, QLT's Visudyne, a drug aimed at treating a form of age-related blindness, will be reviewed by an advisory committee of the U.S. Drug and Food Administration. Mr. Gibbs expects the FDA to recommend approval for Visudyne. That would set the stage for the drug to get final approval for use in the United States by the end of the year. "The FDA almost always follows the advisory committee's recommendations," Mr. Gibbs said in a research note. (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next